MA35024B1 - Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine - Google Patents

Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine

Info

Publication number
MA35024B1
MA35024B1 MA36302A MA36302A MA35024B1 MA 35024 B1 MA35024 B1 MA 35024B1 MA 36302 A MA36302 A MA 36302A MA 36302 A MA36302 A MA 36302A MA 35024 B1 MA35024 B1 MA 35024B1
Authority
MA
Morocco
Prior art keywords
tropomyosin
pyrrolo
inhibitors
pyrimidine derivatives
related kinases
Prior art date
Application number
MA36302A
Other languages
English (en)
Inventor
Mark David Andrews
Sharanjeet Kaur Bagal
Karl Richard Gibson
Kiyoyuki Omoto
Thomas Ryckmans
Sarah Elizabeth Skerratt
Paul Anthony Stupple
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35024(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA35024B1 publication Critical patent/MA35024B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (I) et leurs sels pharmaceutiquement acceptables, les substituants étant tels que décrits dans le présent document, et leur utilisation en médecine, en particulier tant qu'antagonistes de la Trk.
MA36302A 2011-04-05 2012-03-22 Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine MA35024B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471758P 2011-04-05 2011-04-05
PCT/IB2012/051363 WO2012137089A1 (fr) 2011-04-05 2012-03-22 Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des kinases associées à la tropomyosine

Publications (1)

Publication Number Publication Date
MA35024B1 true MA35024B1 (fr) 2014-04-03

Family

ID=45937493

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36302A MA35024B1 (fr) 2011-04-05 2012-03-22 Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine

Country Status (31)

Country Link
US (2) US8846698B2 (fr)
EP (1) EP2694509B1 (fr)
JP (1) JP5595616B2 (fr)
KR (1) KR20130133905A (fr)
CN (1) CN103534257A (fr)
AP (1) AP2013007159A0 (fr)
AR (1) AR085852A1 (fr)
AU (1) AU2012238369A1 (fr)
BR (1) BR112013025792A2 (fr)
CA (1) CA2832291C (fr)
CL (1) CL2013002821A1 (fr)
CO (1) CO6801740A2 (fr)
CR (1) CR20130470A (fr)
CU (1) CU20130129A7 (fr)
DO (1) DOP2013000221A (fr)
EA (1) EA201391239A1 (fr)
EC (1) ECSP13013009A (fr)
ES (1) ES2581848T3 (fr)
GE (1) GEP20156417B (fr)
GT (1) GT201300236A (fr)
IL (1) IL228590A0 (fr)
MA (1) MA35024B1 (fr)
MX (1) MX2013011612A (fr)
NI (1) NI201300103A (fr)
PE (1) PE20141050A1 (fr)
SG (1) SG193513A1 (fr)
TN (1) TN2013000394A1 (fr)
TW (1) TWI443101B (fr)
UA (1) UA108926C2 (fr)
UY (1) UY34004A (fr)
WO (1) WO2012137089A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2873060A1 (fr) * 2012-05-11 2013-11-14 Abbvie Inc. Inhibiteurs de nampt
CA2885253A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associee a la tropomyosine pyrrolo[2,3-d]pyrimidine
US20150250785A1 (en) * 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
EA035929B1 (ru) 2013-01-15 2020-09-02 Инсайт Холдингс Корпорейшн ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
JP2016169161A (ja) * 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
CN105814013A (zh) 2013-12-12 2016-07-27 卡利拉制药公司 双环烷基化合物及合成
WO2015092610A1 (fr) 2013-12-20 2015-06-25 Pfizer Limited Inhibiteurs de kinase apparentés à la n-acylpipéridine éther tropomyosine
CA2937074A1 (fr) * 2014-01-24 2015-07-30 Abbvie Inc. Derives furo-3-carboxamide et methodes d'utilisation
CN109820853B (zh) * 2014-02-05 2022-05-10 Vm肿瘤药物有限责任公司 取代的杂环化合物在制备治疗癌症药物中的用途
JP6741343B2 (ja) 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
WO2015143654A1 (fr) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
EP3140298A1 (fr) * 2014-05-07 2017-03-15 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
CN103992319B (zh) * 2014-05-27 2015-09-16 天津市斯芬克司药物研发有限公司 一种吡啶羧酸类化合物的制备方法
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
JP6833677B2 (ja) * 2014-09-17 2021-02-24 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 二環式化合物
BR112017012566B1 (pt) 2014-12-18 2024-01-30 Genzyme Corporation Forma cristalina monohidratada, composição e formulações farmacêuticas de inibidores de cinases relacionadas à tropomiosina (trk)
JP6675324B2 (ja) * 2014-12-24 2020-04-01 武田薬品工業株式会社 複素環化合物
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017027883A1 (fr) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomérisme pour une sélectivité accrue des inhibiteurs de kinase
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2017220516A1 (fr) * 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Dérivés de triazolo[4,5-d]pyrimidine
CN107011347B (zh) * 2017-04-18 2019-01-18 华东师范大学 一种4-氯-7H-吡咯并[2,3-d]嘧啶的合成方法
CA3063729A1 (fr) 2017-05-15 2018-11-22 Recurium Ip Holdings, Llc Composes analgesiques
WO2018237134A1 (fr) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomérisme pour une sélectivité améliorée des inhibiteurs de kinase
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10807987B2 (en) * 2018-03-28 2020-10-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN109053575A (zh) * 2018-08-24 2018-12-21 遵义医学院 3-环丙基-1-甲基-1h-吡唑-4-甲醛的制备工艺
WO2020084389A1 (fr) * 2018-10-23 2020-04-30 Lupin Limited Intermédiaire de ribociclib et son procédé de préparation
EP3897670A4 (fr) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs
CA3129665A1 (fr) 2019-03-21 2020-09-24 Onxeo Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
AR122141A1 (es) 2020-05-28 2022-08-17 Lilly Co Eli Inhibidor de trka
CN115043844B (zh) * 2021-06-21 2024-05-17 河南迈英诺医药科技有限公司 Trk激酶抑制剂化合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW438796B (en) 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
WO2000035296A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum
HUP0001507A3 (en) * 1997-03-19 2002-01-28 Abbott Gmbh & Co Kg Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2001072751A1 (fr) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
GB0218168D0 (en) * 2002-08-06 2002-09-11 Astrazeneca Ab Compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US20070185079A1 (en) 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
EP1773836B1 (fr) * 2004-05-27 2012-09-05 Pfizer Products Inc. Derives pyrrolopyrimidiniques convenant au traitement du cancer
EP1885723A2 (fr) * 2005-05-17 2008-02-13 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
RU2323058C1 (ru) 2006-07-12 2008-04-27 ООО Научно-внедренческий центр "Машины и оборудование для энергетики" Способ формирования наружной резьбы на концевом участке трубной заготовки
AP2780A (en) 2006-10-18 2013-09-30 Pfizer Prod Inc Biaryl ether urea compounds
EP2094701A2 (fr) 2006-12-21 2009-09-02 Plexxikon, Inc. Composés et procédés pour la modulation de kinases et indications pour celle-ci
WO2008118758A1 (fr) 2007-03-23 2008-10-02 Icagen, Inc. Inhibiteurs de canaux ioniques
CA2684105C (fr) 2007-05-03 2011-09-06 Pfizer Limited Derives de la pyridine
WO2009012242A2 (fr) 2007-07-13 2009-01-22 Icagen, Inc. Inhibiteurs des canaux sodiques
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
WO2009143018A2 (fr) 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
AU2009257635A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症

Also Published As

Publication number Publication date
CU20130129A7 (es) 2014-01-29
CR20130470A (es) 2013-10-16
CL2013002821A1 (es) 2014-02-21
TW201302757A (zh) 2013-01-16
WO2012137089A1 (fr) 2012-10-11
CA2832291A1 (fr) 2012-10-11
US20120258950A1 (en) 2012-10-11
GT201300236A (es) 2015-08-04
UY34004A (es) 2012-11-30
GEP20156417B (en) 2015-12-25
BR112013025792A2 (pt) 2018-04-24
US8846698B2 (en) 2014-09-30
IL228590A0 (en) 2013-12-31
DOP2013000221A (es) 2014-03-16
CA2832291C (fr) 2015-12-01
NZ615557A (en) 2014-08-29
TWI443101B (zh) 2014-07-01
TN2013000394A1 (fr) 2015-01-20
NI201300103A (es) 2014-02-12
AR085852A1 (es) 2013-10-30
UA108926C2 (ru) 2015-06-25
AU2012238369A1 (en) 2013-10-03
EA201391239A1 (ru) 2014-03-31
MX2013011612A (es) 2013-10-17
CN103534257A (zh) 2014-01-22
EP2694509B1 (fr) 2016-05-18
PE20141050A1 (es) 2014-08-30
EP2694509A1 (fr) 2014-02-12
SG193513A1 (en) 2013-10-30
ECSP13013009A (es) 2013-12-31
CO6801740A2 (es) 2013-11-29
JP2014510131A (ja) 2014-04-24
KR20130133905A (ko) 2013-12-09
JP5595616B2 (ja) 2014-09-24
AP2013007159A0 (en) 2013-10-31
ES2581848T3 (es) 2016-09-07
US20140364415A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
MA35024B1 (fr) Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA38138A1 (fr) Dérivés inédits de quinolone
MA37405A1 (fr) Composés hétérocyclyle
DOP2014000303A (es) 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA35451B1 (fr) Dérivés de pyrrolopyrimidine et de purine
MA38922A2 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
RS54339B1 (en) NEW ANTIMALARIAN AGENTS
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
MA37886A1 (fr) Nouvelles pyridinones bicycliques
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA38112A1 (fr) Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA38857B1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines